Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved EGFR tyrosine kinase inhibitors (TKIs) as a first choice of treatment. The median response duration of TKIs as a first...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jae Cheol, Jang, Seung Hun, Lee, Kye Young, Kim, Young-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710966/
https://www.ncbi.nlm.nih.gov/pubmed/23864840
http://dx.doi.org/10.4143/crt.2013.45.2.79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710966/
https://www.ncbi.nlm.nih.gov/pubmed/23864840
http://dx.doi.org/10.4143/crt.2013.45.2.79

Ejemplares similares